Hot off the Forge
-
Partnership will advance Eikonoklastes’ AAV-based gene therapy, ET-101, into clinical trials for the treatment of patients with amyotrophic lateral sclerosis…
-
The data from treated subjects demonstrate that intravenous FBX-101 after HSCT infusion has been safe and well tolerated.
-
Building on an AAV manufacturing partnership with new plasmid production, Forge’s end-to-end manufacturing services will help to advance Ray’ gene…
-
The partnership will help advance Myrtelle’s novel gene therapy for monogenic hearing loss, Myr-201, into clinical trials for patients with…
-
Conferences include upcoming Jefferies, Chardan, and SVB Securities healthcare conferences.
-
New offering complements Forge’s existing AAV process development, analytical development, cGMP manufacturing, and automated final fill capabilities.
-
This round brings the total capital raised to $330 million since Forge’s launch in 2020.
-
Christina Perry, Senior Vice President of Finance & Investor Relations, will be delivering the presentation to investors.
-
Novel approach may lessen many of the immune challenges previously observed with systemic AAV gene delivery.
-
“Forge has grown to over 220 employees and we’re excited to share how we are enabling manufacturing success for our…
-
The board will serve Forge with a distinct and strategic emphasis on manufacturing advancements.
-
Five scientific poster presentations highlight scalable process and analytical developments for AAV manufacturing.